WO1997017367A1 - Technique de synthese de peptides grf - Google Patents
Technique de synthese de peptides grf Download PDFInfo
- Publication number
- WO1997017367A1 WO1997017367A1 PCT/CA1996/000712 CA9600712W WO9717367A1 WO 1997017367 A1 WO1997017367 A1 WO 1997017367A1 CA 9600712 W CA9600712 W CA 9600712W WO 9717367 A1 WO9717367 A1 WO 9717367A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ala
- grf
- segments
- ser
- gly
- Prior art date
Links
- 238000003786 synthesis reaction Methods 0.000 title claims abstract description 30
- 230000015572 biosynthetic process Effects 0.000 title claims abstract description 29
- 238000000034 method Methods 0.000 title claims abstract description 29
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 25
- 102000004196 processed proteins & peptides Human genes 0.000 title description 8
- 101710142969 Somatoliberin Proteins 0.000 claims abstract description 57
- 238000010168 coupling process Methods 0.000 claims abstract description 27
- 230000008878 coupling Effects 0.000 claims abstract description 26
- 238000005859 coupling reaction Methods 0.000 claims abstract description 26
- 150000001408 amides Chemical class 0.000 claims abstract description 17
- 239000011347 resin Substances 0.000 claims abstract description 12
- 229920005989 resin Polymers 0.000 claims abstract description 12
- 239000007790 solid phase Substances 0.000 claims abstract description 11
- 230000002378 acidificating effect Effects 0.000 claims abstract description 10
- 238000004519 manufacturing process Methods 0.000 claims abstract description 6
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims abstract description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 15
- -1 Phe Chemical compound 0.000 claims description 14
- 210000004899 c-terminal region Anatomy 0.000 claims description 11
- 239000001257 hydrogen Substances 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 125000003277 amino group Chemical group 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 6
- 125000003342 alkenyl group Chemical group 0.000 claims description 5
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Chemical group OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims description 4
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 claims description 4
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical group OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims description 4
- OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 claims description 4
- 125000002252 acyl group Chemical group 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- 125000001424 substituent group Chemical group 0.000 claims description 3
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 2
- DCXYFEDJOCDNAF-UWTATZPHSA-N D-Asparagine Chemical compound OC(=O)[C@H](N)CC(N)=O DCXYFEDJOCDNAF-UWTATZPHSA-N 0.000 claims description 2
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 claims description 2
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 claims description 2
- HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical compound OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 claims description 2
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 claims description 2
- SGCGMORCWLEJNZ-UWVGGRQHSA-N His-His Chemical compound C([C@H]([NH3+])C(=O)N[C@@H](CC=1NC=NC=1)C([O-])=O)C1=CN=CN1 SGCGMORCWLEJNZ-UWVGGRQHSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
- 125000005431 alkyl carboxamide group Chemical group 0.000 claims description 2
- 125000000539 amino acid group Chemical group 0.000 claims description 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 150000002431 hydrogen Chemical group 0.000 claims description 2
- 230000002209 hydrophobic effect Effects 0.000 claims description 2
- 150000002596 lactones Chemical class 0.000 claims description 2
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000005499 phosphonyl group Chemical group 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 2
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 2
- FFEARJCKVFRZRR-SCSAIBSYSA-N D-methionine Chemical compound CSCC[C@@H](N)C(O)=O FFEARJCKVFRZRR-SCSAIBSYSA-N 0.000 claims 1
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 claims 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 claims 1
- 102100022831 Somatoliberin Human genes 0.000 abstract description 31
- 238000012935 Averaging Methods 0.000 abstract description 2
- 108010051696 Growth Hormone Proteins 0.000 description 35
- 102000018997 Growth Hormone Human genes 0.000 description 35
- 239000000122 growth hormone Substances 0.000 description 34
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 20
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 15
- 230000028327 secretion Effects 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 8
- 238000003776 cleavage reaction Methods 0.000 description 8
- 230000007017 scission Effects 0.000 description 8
- 206010062767 Hypophysitis Diseases 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 210000003635 pituitary gland Anatomy 0.000 description 7
- 125000006239 protecting group Chemical group 0.000 description 7
- 230000004071 biological effect Effects 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 5
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 4
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 101001075374 Homo sapiens Gamma-glutamyl hydrolase Proteins 0.000 description 3
- 101000664737 Homo sapiens Somatotropin Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- UNXNGGMLCSMSLH-UHFFFAOYSA-N dihydrogen phosphate;triethylazanium Chemical compound OP(O)(O)=O.CCN(CC)CC UNXNGGMLCSMSLH-UHFFFAOYSA-N 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 102000005157 Somatostatin Human genes 0.000 description 2
- 108010056088 Somatostatin Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 108010006025 bovine growth hormone Proteins 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000003578 releasing effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 2
- 229960000553 somatostatin Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010013883 Dwarfism Diseases 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 208000012766 Growth delay Diseases 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000825742 Homo sapiens Somatoliberin Proteins 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229920000361 Poly(styrene)-block-poly(ethylene glycol) Polymers 0.000 description 1
- 208000020221 Short stature Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000026928 Turner syndrome Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229940124325 anabolic agent Drugs 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000003857 carboxamides Chemical group 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000005115 demineralization Methods 0.000 description 1
- 230000002328 demineralizing effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- AQEFLFZSWDEAIP-UHFFFAOYSA-N di-tert-butyl ether Chemical compound CC(C)(C)OC(C)(C)C AQEFLFZSWDEAIP-UHFFFAOYSA-N 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229940000673 orphan drug Drugs 0.000 description 1
- 239000002859 orphan drug Substances 0.000 description 1
- 238000004647 photon scanning tunneling microscopy Methods 0.000 description 1
- 208000003068 pituitary dwarfism Diseases 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 210000001875 somatotroph Anatomy 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the invention relates to a high yield synthesis methodology of GRF peptides .
- GH Growth hormone
- IGF-I insulin-like growth factor-I
- EGF epidermal growth factor
- GH Through its action on IGF-I (somatomedin C) synthesis and secretion, GH stimulate the growth of the cartilage and the bones (structural growth), the protein synthesis and the cellular proliferation in multiple peripheral organs, including muscles and the skin. Through its biological activity, GH participates within adults at the maintenance of a protein anabolism state, and plays a primary role in the tissue regeneration phenomenon after a trauma.
- IGF-I somatomedin C
- GH secretion with the age, demonstrated in humans and animals, favors a metabolic shift towards catabolism which initiates or participate to the aging of an organism.
- GH is thus a physiological anabolic agent absolutely necessary for the linear growth of children and which controls the protein metabolism in adults.
- the secretion of GH by the pituitary gland is principally controlled by two hypothalamic peptides, somatostatin and growth hormone-releasing factor (GRF).
- Somatostatin inhibits its secretion, whereas GRF stimulates it.
- the human GH has been produced by genetic engineering for about ten years. Until recently most of the uses of GH were concerned with growth delay in children and now the uses of GH in adults are studied. The pharmacological uses of GH and GRF may be classified in the following three major categories.
- Recombinant human growth hormone Treatments with recombinant human growth hormone have been shown to stimulate growth in children with pituitary dwarfism, renal insufficiencies, Turner's syndrome and short stature.
- Recombinant human GH is presently commercialized as an "orphan drug" in Europe and in the United States for children's growth retardation caused by a GH deficiency and for children's renal insufficiencies. The other uses are under clinical trial investigation.
- Preliminary studies of one-year treatment with recombinant human GH reported an increase in the muscle mass and in the thickness of skin, a decrease in fat mass with a slight increase in bone density in a population of aged patients.
- Short term treatment in adults and elderly patients
- GH and GRF are also intended for veterinary pharmacological uses. Both GH and GRF stimulate growth in pigs during its fattening period by favoring the deposition of muscle tissues instead of adipose tissues and increase milk production in cows, and this without any undesired side effects which would endanger the health of the animals and without any residue in the meat or milk being produced.
- the bovine somatotropin (BST) is presently commercialized in the United States.
- GRF is considered as a second generation product destined to replace in the near future the uses of GH in most instances. Accordingly, the use of GRF presents a number of advantages over the use of GH per se.
- GRF Growth hormone
- the recombinant GH which is presently commercialized is the 21.5 kDa form whereas GRF induces the synthesis and secretion from the pituitary gland of all the chemical isomers of GH which participate in a wider range of biological activities.
- a treatment with GH results in a decreased capacity of the pituitary gland to secrete endogenous growth hormone, and the GH response to GRF is diminished after such a treatment.
- a treatment with GRF does not present this disadvantages, its trophic action on the pituitary gland increases this gland secreting capacity in normal animals and in patients with somatotroph insufficiency. Economical advantages
- GH proliferative growth factor
- genetic engineering is very expensive for clinical use.
- These bacterial contaminants may be pyrogens or may result in immunogenic reactions in patients.
- the purification of the recombinant product is effected by following a plurality of successive chromatography steps. The drastic purity criteria causes multiple quality control steps.
- the synthesis of GRF is of chemical nature.
- the synthesis effected in a solid phase and its purification is carried out in a single step using high performance liquid chromatography (HPLC).
- HPLC high performance liquid chromatography
- the quantity of GRF to be administered is much less than the quantity of GH for the same resulting biological activity.
- the human GRF is a peptide of 44 amino acids of the following sequence :
- Solid phase step by step chemical synthesis is the most useful way known to date for synthesis of many peptides, including GRF peptides.
- the step by step chemical synthesis involved reagent consumption and side reactions such that a single dose may become of a very high cost.
- the step by step synthesis of hGRF(1-29)NH 2 is well known to yield about 20% of pure material, while the synthesis of hGRF(1-44)NH 2 allow only to a 5% to 10% yield. This constitute one of the main disadvantages in the commercial availability of GRF peptides.
- the GRF peptides segment coupling methodology of the present invention provides the ultimate solution of this fundamental problem.
- the method of the present invention particularly allows the coupling of long segments such as GRF peptide segment (1-15)-OH + segment (1-29)NH-; segment (1-15)-OH + segment (16-32) + segment (33-44)-NH-, among others.
- the step by step method of the prior art uses only shorter segments of 5, 6 or 7 residues.
- the present invention relates particularly to a high yield manufacturing process of (Gly or Ala) 15 or 32 GRF containing peptide comprising:
- the present invention relates to a segment coupling process of GRF peptides.
- the invention relates to the coupling of GRF peptide segments comprising the equations (1) to (4):
- amino acids are identified by the conventional three-letter abbreviations as indicated below, which are as generally accepted in the peptide art as recommended by the IUPAC-IUB commission in biochemical nomenclature.
- GRF peptide The nomenclature used to define the GRF peptide is that specified by Schroder & Lubke, "The peptides", Academic Press (1965) wherein in accordance with conventional representation, the amino group at the N- terminal appears to the left and the carboxyl group at the C-terminal to the right.
- GRF peptides as used herein is intended to means a known polypeptide which is between about 25 and 44 residues, preferably between 27 and 44 residues in length, which contains gly or Ala in position 15 and/or 32 and which polypeptide promotes the release of growth hormone by the pituitary gland.
- Illustrative GRF peptides include the natural or synthetic polypeptides disclosed in U.S. Patents Nos.
- GRF peptides are synthesized in accordance with the present invention:
- Fig. 1 is a schematic representation of the synthesis of hGRF(1-29) in accordance with the present invention.
- the present invention relates to a segment couplings process of GRF peptides.
- the invention relates to the coupling of GRF peptide segments comprising the sequence:
- Q is 3-(5-hydroxyindolyl)-methyl or an omega or alpha-omega substituted alkyl of the following structure: (HO) m -[ ⁇ ]-(CH 2 ) n -C(R 4 )(R 5 )- wherein,
- [ ⁇ ] is phenyl
- R 4 is H, NH 2 , CH 3 -CO-NH-, CH 3 -NH-;
- R 5 is H or CH 3 -;
- n 1 or 2;
- n 0,1 or 2;
- Q0 is hydrogen or any hydrophobic tail selected from the following formula:
- G is preferably a carbonyl, but may also be a phosphonyl, a sulfuryl or a sulfinyl group, with "a" being zero or 1;
- X is an oxygen atom, or an amino group, with b having the value of zero or 1;
- R 1 , R 2 and R 3 are identical or different, and are either hydroxyl groups, hydrogen or lower linear or branched alkyl groups; c and g can be
- R 6 is an hydroxyl group, hydrogen or C 4 -C 9 alkyl, with e varying from zero to 6;
- Z is an amino group -NH-; h varies from zero to
- Q 1 is Tyr, His, des-amino Tyr, D-Tyr, Met, Phe,
- Q 2 is Ala, D-Ala, (D or L) N- ⁇ Me-Ala, Val, D- Val, Abu, Aib or D-Arg;
- Q 3 is Asp or D-Asp
- Q 7 is Thr, Aib, Leu, Trp, ⁇ -Nal, or p-X-Phe, in which X is H, F, Cl, Br, NO, -OMe, or Me;
- Q 8 is Asn, D-Asn, Ser, D-Ser, Abu, Ala, Aib,
- Trp Trp
- ⁇ -Nal Trp
- p-X-Phe in which X is H, F, Cl, Br, NO 2 , -OMe, or Me;
- Q 9 is Ser, Thr, Ala, Aib, Leu, Trp, ⁇ -Nal, or p-X-Phe, in which X is H, F, Cl, Br, NO 2 , -OMe, or Me;
- Q 10 is Tyl or D-Tyr
- Q 12 and Q 21 are Lys, Arg, or N e -I-Lys in which
- I is lower alkyl, acyl, alkenyl, acenyl or cycloalkyl, Q 12 an Q 21 may be the same or different;
- Q 13 is Ile or Val
- Q 14 , Q 17 , Q 23 and Q 26 are Leu, Ile, D-Leu or D- Ile and may be the same or different;
- Q 15 is Gly or Ala
- Q 18 is Tyr or Ser
- Q 24 is His or Gln
- Q 25 is Glu, Asp, D-Glu or D-Asp
- Q 27 is Met, D-Met, Ala, Nle, Ile, Leu, Nva,
- Q 28 is Asn, Ser or Asp
- Q 29 is Arg, D-Arg
- R is of the following general formula:
- R 9 is hydrogen, lower alkyl, lower alkenyl, lower aryl , aralkyl or lower alkylcarboxamide;
- Q 30 , Q 31 are Gln or Asn and may be identical or different
- Q 32 is gly or Ala, preferably Gly;
- Q 34 is ser or Arg
- Q 35 is Asn or Ser
- Q 38 is Arg or Gln;
- Q 39 is Gly or Arg;
- Q 40 is Ala or Ser
- Q 42 is Ala, Val or Phe
- R 3 represent the whole carboxyl moiety of the amino acid residue at the C-terminal and is the radical -COOR 4 , -COR 4 , -CO-NHNH-R 4 , -CO- N(R 4 )(R 5 ) or -CH 2 -OR 4 , with R 4 and R 5 being hydrogen or C 1 -C 8 alkyl or a biologically active fragment thereof extending from Q at the N-terminus to a residue in any of position 20 to 44 at its C-terminus; or a Hse(lactone), a
- One of the preferred embodiment of the high yield method of synthesis of the present invention relates to the coupling of GRF peptide segments as shown in Fig. 1.
- the N-alpha amino group of Tyr 1 as well as the side chain of Lys 12 are protected as Boc group.
- Side chains of Tyr 1,10 , Ser 9 and Thr 7 are protected as tert-butyl ether.
- the side chain of Arg 11 is protected as Pmc or Pbf group.
- Side chain of Asn 8 is protected as trityl and side chain of Asp is protected as tert-butyl ester.
- Another embodiment of the high yield method of synthesis of the present invention relates to the coupling of GRF peptide segments coupling shown in equation (1),
- a preferred embodiment of the present invention relates to the segment coupling shown in equation (5) above, wherein the N-terminal Boc group in Tyr 1 is replaced by the group hexanoyl. This will result in a final peptide as an hexanoyl-Tyr 1 hGRF(1-29) amide after final cleavage in TFA.
- the most preferred embodiment of this invention relates to the coupling shown in equation (5), wherein the N-terminal Boc group of Tyri is substituted by the group hexenoyl (cis or trans)-3-. This will afford a final peptide as a (cis or trans)-3-hexenoyl-Tyr 1 hGRF(1-29) amide, after cleavage in TFA .
- Another embodiment of the high yield method of synthesis of the present invention relates to any of the foregoing embodiments wherein Met is substituted for He in position 27 and/or Tyr is substituted for His in position 1.
- GRFs peptides segments as well as GRFs peptides using the strategy of the present invention when compared to the step by step coupling strategy of the prior art, is illustrated in Table 1 below.
- C-terminal acidic segments are synthesized manually on sasrin resin (Bachem California, catalog part number RMIS45). In these conditions, the first amino acid is linked to the resin using DIC/DMAP methodology. C-terminal amide segments are synthesized on Pal-PEG-PSTM support (Perspective biosystem, part number GEN 913383), utilizing a Millipore 9050TM plus peptide synthesizer and synthesis cycle supplied by Millipore.
- Solvents such as DMF and DCM are of HPLC grade and are purchased from Anachemia Sciences. Fmoc amino acid and other reagents are supplied by Synpep Corporation and other commercial sources. Sequential Fmoc Chemistry using double couple protocols are applied to the starting Pal-PEG-PS.
- Another embodiment of the high yield method of synthesis of the present invention relates to resin for the production of C-terminal carboxamide. Both, aminoacid and segment are coupled using HBTU/HOBt or other coupling methodology. The following side chain protection is used.
- the minimum segment length is of 14 residues for segments 1 and 2, and of 12 residues for segments 3, 4 and 5.
- the fully protected acidic segment e.g. (S 1 )-OH or (S 2 )-OH
- S 1 )-OH or (S 2 )-OH is then afforded by selective cleavage of the peptide resin bond in extremely mild conditions, usually 0.5% TFA in dichloromethane.
- the coupling efficiency for the synthesis of hexanoyl-Tyr 1 hGRF(1-29) NH 2 is determined by weight , while the purity is determined by HPLC or by TLC for protected individual segments.
- the mixture CHCl 3 /MeOH/80% Ac-OH (16:1:1) side chain protected acidic segments hexanoyl-Tyr 1 hGRF (1-15)-OH and trans-3-hexenoyl-Tyr 1 hGRF(1-15)-OH gave respectively in TLC, the RF value of 0.47 and 0.49. Again the RF value is the ratio between the migration level of the compound versus the migration level of the eluent.
- Segment couplings can be performed either by solid phase or in solution synthesis, both resulting in a high yield average of about 65-68% for any 29 or 32 amino acids GRF peptides.
- the methodology provides also another advantage characterized in that, excess of acidic segment to be coupled can be quantitatively regenerated after coupling by precipitation and washings with water.
- the side chain protected C-terminal amide segment (e.g. segment 3 for hGRF(16-29)amide) is appropriately made using the step by step methodology and kept as a N-terminal free amine on resin. Then acidic GRF peptide segment bearing protecting groups for its alpha amino group (and, where appropriate, for its amino acid side chain) is coupled in a minimum amount of DMF. After completion of this coupling step, the N-alpha amino protecting group (if any), is removed from this newly anchored segment and the next segment (if any), suitably protected, is added and so forth.
- the N-terminal protecting groups are removed after each residue is added, but the side chain protecting groups are not yet removed.
- the peptide is cleaved from the support and then freed from any side chain protecting groups.
- Such cleavage is performed under conditions that are minimally destructive toward residue in sequence (e.g. in TFA/H 2 O/scavenger), as in procedure supplied by Millipore.
- the suspension is filtered off and the solution is precipitated , washed with ether and dried. Example of improved yield using this methodology is shown in Table 1 above.
- Purification is carried out by reverse phase chromatography on a WatersTM prep. 4000 equipped with 3 cartridges (25 ⁇ 100mm, DeltaTM pak C 18 ) at a flow rate of 50 ml per min.
- the peptide is applied using TEAP buffer at pH 2.5 and eluated with a 90 min. gradient consisting of: Buffer A: TEAP pH 2.5; Buffer B: 80% CH 3 CN/TEAP and starting from 20% B under the isocratic conditions (analytical column DeltaTM pak C18 6 ⁇ 250mm) and ending at 10 % B above.
- Fractions with minimum purity of 95 % are then pooled and desalted using buffers C: 0.1% TFA in H 2 O and D: 0.1% TFA in CH 3 CN / H 2 O(80:20).
- the free acid segment to be coupled is properly protected during the coupling step with appropriate acid or base sensitive protecting groups.
- protecting groups should have the properties of being stable in the conditions of peptide linkage formation, while being readily removable without destruction of the growing peptide chain or racemization of any of the chiral centers contained herein.
- the in vivo growth hormone releasing activities for hexanoyl-Tyr 1 hGRF(1-29) amide synthesized by solid segment coupling methodology outlined for this invention is summarized in Table 2 and 3 in comparison to hGRF(1-29) and hexanoyl-Tyr 1 hGRF (1-29) amide synthesized using solid phase step by step methodology.
- the Table 2 is shown for intravenous injection while the Table 3 for subcutaneous injection.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU72731/96A AU7273196A (en) | 1995-11-03 | 1996-10-28 | Method of grf peptides synthesis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55259695A | 1995-11-03 | 1995-11-03 | |
US08/552,596 | 1995-11-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997017367A1 true WO1997017367A1 (fr) | 1997-05-15 |
Family
ID=24206010
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA1996/000712 WO1997017367A1 (fr) | 1995-11-03 | 1996-10-28 | Technique de synthese de peptides grf |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU7273196A (fr) |
WO (1) | WO1997017367A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999027897A1 (fr) * | 1997-12-03 | 1999-06-10 | Applied Research Systems Ars Holding N.V. | Preparation specifique a un site de conjugues de polyethylene glycol-grf |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0193910A2 (fr) * | 1985-03-06 | 1986-09-10 | Sumitomo Pharmaceuticals Company, Limited | Synthèse d'un dérivé du "GRF" et peptides intermédiaires |
FR2599038A1 (fr) * | 1986-05-26 | 1987-11-27 | Sanofi Sa | Procede de preparation de nonacosapeptides et peptides intermediaires |
WO1994011397A1 (fr) * | 1992-11-13 | 1994-05-26 | The Administrators Of The Tulane Educational Fund | Agonistes de somatostatine |
EP0606816A1 (fr) * | 1992-12-10 | 1994-07-20 | Lipotec, S.A. | Procédé de préparation de la calcitonine du saumon |
-
1996
- 1996-10-28 WO PCT/CA1996/000712 patent/WO1997017367A1/fr active Application Filing
- 1996-10-28 AU AU72731/96A patent/AU7273196A/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0193910A2 (fr) * | 1985-03-06 | 1986-09-10 | Sumitomo Pharmaceuticals Company, Limited | Synthèse d'un dérivé du "GRF" et peptides intermédiaires |
FR2599038A1 (fr) * | 1986-05-26 | 1987-11-27 | Sanofi Sa | Procede de preparation de nonacosapeptides et peptides intermediaires |
WO1994011397A1 (fr) * | 1992-11-13 | 1994-05-26 | The Administrators Of The Tulane Educational Fund | Agonistes de somatostatine |
EP0606816A1 (fr) * | 1992-12-10 | 1994-07-20 | Lipotec, S.A. | Procédé de préparation de la calcitonine du saumon |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999027897A1 (fr) * | 1997-12-03 | 1999-06-10 | Applied Research Systems Ars Holding N.V. | Preparation specifique a un site de conjugues de polyethylene glycol-grf |
EP0922446A1 (fr) * | 1997-12-03 | 1999-06-16 | Applied Research Systems Ars Holding N.V. | Préparation des conjugués du GRF-PEG par un méthode en solution spécifique à un site |
US6869932B2 (en) | 1997-12-03 | 2005-03-22 | Applied Research Systems Ars Holding N.V. | Site-specific preparation of polyethlene glycol-GRF conjugates |
US7317002B2 (en) | 1997-12-03 | 2008-01-08 | Applied Research Systems Ars Holding N.V. | Site-specific preparation of polyethylene glycol-GRF conjugates |
Also Published As
Publication number | Publication date |
---|---|
AU7273196A (en) | 1997-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5939386A (en) | Chimeric fatty body-pro-GRF (1-29) analogs with increased biological potency | |
DE60035502T2 (de) | Neue peptide | |
FI92210C (fi) | Menetelmä farmaseuttisesti käyttökelpoisten GRF-analogien valmistamiseksi | |
EP0177819B1 (fr) | Analogues du facteur libérant l'hormone de croissance et leur procédé | |
DE69630133T2 (de) | Analoga des parathyroid-hormons | |
US5696089A (en) | Histidine substituted growth hormone releasing factor analogs | |
US4622312A (en) | Growth hormone releasing factor analogs | |
IL101452A (en) | Analogs of the factor that releases the growth hormone, their preparation and the pharmaceutical preparations that contain them | |
US4562175A (en) | Synthetic peptides | |
JPS59501951A (ja) | ヒト膵臓grf | |
US4610976A (en) | Porcine GRF | |
US6020311A (en) | GRF analogs with increased biological potency | |
KR0138907B1 (ko) | 합성 펩티드 | |
US4734399A (en) | Growth hormone releasing factor analogs | |
MX2014007402A (es) | Nuevos analogos de gh-rh con potentes efectos agonistas. | |
KR900006560B1 (ko) | Grf 유사체의 제법 | |
KR0163033B1 (ko) | Grf 유사체 viia | |
EP0107890B1 (fr) | PGRF de mammifères | |
WO1997017367A1 (fr) | Technique de synthese de peptides grf | |
IE64494B1 (en) | Cyclic grf-analogs | |
US4959352A (en) | Cyclic growth hormone releasing factor analogs and method for the manufacture thereof | |
MXPA97009098A (en) | Chemical analogues of body grease-pro with biological power increment | |
HU205953B (en) | Process for producing new analogues of growth hormon secretion stimulating hormon and pharmaceutical and veterinaryc compositions containing them as active components |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 97517700 Format of ref document f/p: F |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |